Emergent BioSolutions | EBS - Ebit

Aktienkurs
9.50
Täglich Wechseln
0.37 4.05%
Monatlich
12.43%
Jährlich
68.14%
Q2 Prognose
8.94




Ebit Veränderung Datum
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
ALKERMES USD -48.28M 37.33M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amarin USD -2.26M 564K 2025-12
ANI Pharmaceuticals USD 38.71M 9.58M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Coherus Biosciences USD -39.08M 3.65M 2025-12
Exelixis USD 251.34M 15.43M 2026-03
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -118M 97M 2026-03
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
Lexicon Pharmaceuticals USD -14.78M 2.59M 2025-12
Lonza CHF 673M 54M 2025-06
Merck USD -1.88B 8.12B 2026-03
Moderna USD -1.39B 531M 2026-03
Myriad Genetics USD -3M 20.3M 2025-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Pacira USD 4.62M 1.43M 2026-03
Pfizer USD 4.99B 340M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Sanofi EUR 1.94B 239M 2026-03
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
United Therapeutics USD 325.8M 340.4M 2026-03
Vanda Pharmaceuticals USD -10.28M 721K 2024-12
Xoma USD -10.08M 4.4M 2024-06